Literature DB >> 30616803

High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma.

Sulsal Haque1, Vidhya Karivedu1, Muhammed K Riaz1, David Choi2, Logan Roof1, Sarah Z Hassan1, Zheng Zhu3, Roman Jandarov3, Vinita Takiar4, Alice Tang2, Trisha Wise-Draper5.   

Abstract

OBJECTIVES: Salvage surgical resection is the preferred treatment for head and neck squamous cell carcinoma (HNSCC) patients who develop locally recurrent disease after failing primary therapy. However, salvage surgical resection is not always feasible, and survival outcomes for those that do undergo salvage remain poor. It is well known that patients with adverse pathological features (extracapsular extension (ECE) of lymph nodes (LN), positive margins, perineural invasion (PNI), lymphovascular invasion (LVI), and multiple LN metastases) at the time of primary surgical resection are likely to have relatively poor outcomes. However, the impact of adverse pathological features on outcomes in the salvage setting remains controversial.
MATERIALS AND METHODS: We retrospectively analyzed 73 patients at a single institution from 2008 to 2017 who developed recurrence and subsequently underwent salvage surgery (SS) after definitive curative-intent therapy including radiation. Demographic and disease control outcomes were reviewed. Kaplan-Meier curves were used to estimate relapse free survival (RFS) and overall survival (OS).
RESULTS: Median age at diagnosis was 61 years (range 40-86), 49/73 (67%) were male, and 55/73 (75%) had smoked. Patients with any adverse pathological features at SS had worse RFS (HR 3.15 p = 0.0008) and worse OS (3.97 p = 0.0008). Patients who relapsed <6 months after initial therapy had worse OS (HR 2.96 p = 0.004).
CONCLUSIONS: Patients with adverse pathological features at time of salvage surgery as well as those who have an early recurrence after definitive treatment and salvage surgery have worse outcomes. Prospective studies are necessary to clarify which patients should receive more intense treatment at salvage.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HNSCC; Head and neck cancer; Salvage surgery

Year:  2018        PMID: 30616803      PMCID: PMC6327963          DOI: 10.1016/j.oraloncology.2018.11.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  28 in total

1.  Salvage surgery after locoregional failure in head and neck carcinoma patients treated with chemoradiotherapy.

Authors:  E Esteller; M C Vega; M López; M Quer; X León
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-19       Impact factor: 2.503

2.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Authors:  Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow
Journal:  Lancet Oncol       Date:  2016-05-27       Impact factor: 41.316

3.  Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses.

Authors:  Jack Phan; Terence T Sio; Theresa P Nguyen; Vinita Takiar; G Brandon Gunn; Adam S Garden; David I Rosenthal; Clifton D Fuller; William H Morrison; Beth Beadle; Dominic Ma; Mark E Zafereo; Kate A Hutcheson; Michael E Kupferman; William N William; Steven J Frank
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-13       Impact factor: 7.038

4.  Salvage surgery after radiotherapy for oropharyngeal cancer. Treatment complications and oncological results.

Authors:  C-A Righini; K Nadour; C Faure; R Rtail; N Morel; V Beneyton; E Reyt
Journal:  Eur Ann Otorhinolaryngol Head Neck Dis       Date:  2011-11-21       Impact factor: 2.080

5.  Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?

Authors:  W J Goodwin
Journal:  Laryngoscope       Date:  2000-03       Impact factor: 3.325

6.  Preoperative [18F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse.

Authors:  Chun-Ta Liao; Joseph Tung-Chieh Chang; Hung-Ming Wang; Shu-Hang Ng; Shiang-Fu Huang; I-How Chen; Chuen Hsueh; Li-Yu Lee; Chih-Hung Lin; Ann-Joy Cheng; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

7.  Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.

Authors:  B Brockstein; D J Haraf; A W Rademaker; M S Kies; K M Stenson; F Rosen; B B Mittal; H Pelzer; B B Fung; M-E Witt; B Wenig; L Portugal; R W Weichselbaum; E E Vokes
Journal:  Ann Oncol       Date:  2004-08       Impact factor: 32.976

8.  Selection of Ideal Candidates for Surgical Salvage of Head and Neck Squamous Cell Carcinoma: Effect of the Charlson-Age Comorbidity Index and Oncologic Characteristics on 1-Year Survival and Hospital Course.

Authors:  JeeHong Kim; Seungwon Kim; William G Albergotti; Phillip A Choi; Daniel James Kaplan; Shira Abberbock; Jonas T Johnson; Neil Gildener-Leapman
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2015-12       Impact factor: 6.223

9.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

10.  Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines.

Authors:  H Mehanna; A Kong; S K Ahmed
Journal:  J Laryngol Otol       Date:  2016-05       Impact factor: 1.469

View more
  3 in total

1.  Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck.

Authors:  Jennifer L Leddon; Shuchi Gulati; Sulsal Haque; Casey Allen; Sarah Palackdharry; Maria Mathews; Nicky Kurtzweil; Muhammed Kashif Riaz; Vinita Takiar; Misako Nagasaka; Yash Patil; Chad Zender; Alice Tang; Brian Cervenka; Julie McGrath; W Michael Korn; Benjamin H Hinrichs; Roman Jandarov; Nusrat Harun; Ammar Sukari; Trisha M Wise-Draper
Journal:  Clin Cancer Res       Date:  2022-08-15       Impact factor: 13.801

2.  Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy.

Authors:  Shane Mesko; He Wang; Samuel Tung; Congjun Wang; Dario Pasalic; Bhavana V Chapman; Amy C Moreno; Jay P Reddy; Adam S Garden; David I Rosenthal; G Brandon Gunn; Steven J Frank; Clifton D Fuller; William Morrison; Jack Phan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-09-30       Impact factor: 7.038

Review 3.  Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications.

Authors:  Irene Paraboschi; Stephen Turnock; Gabriela Kramer-Marek; Layla Musleh; Marta Barisa; John Anderson; Stefano Giuliani
Journal:  Crit Rev Oncol Hematol       Date:  2021-04-06       Impact factor: 6.312

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.